Annovis Bio Inc
$ 1.89
-5.03%
05 Jun - close price
- Market Cap 80,404,000 USD
- Current Price $ 1.89
- High / Low $ 1.96 / 1.85
- Stock P/E N/A
- Book Value 0.62
- EPS -1.71
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.06 %
- ROE -2.21 %
- 52 Week High 5.50
- 52 Week Low 1.54
About
Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania.
Analyst Target Price
$12.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-15 | 2026-03-16 | 2025-11-12 | 2025-08-12 | 2025-05-13 | 2025-03-21 | 2024-11-08 | 2024-08-14 | 2024-05-13 | 2024-03-29 | 2023-11-08 | 2023-08-15 |
| Reported EPS | -0.63 | -0.39 | -0.37 | -0.32 | -0.32 | -0.43 | -0.97 | -0.44 | -0.1 | -2.24 | -1.63 | -1.07 |
| Estimated EPS | -0.35 | -0.31 | -0.37 | -0.39 | -0.8 | -0.2 | -0.6 | -0.67 | -0.84 | -1.3 | -1.09 | -1.14 |
| Surprise | -0.28 | -0.08 | 0 | 0.07 | 0.48 | -0.23 | -0.37 | 0.23 | 0.74 | -0.94 | -0.54 | 0.07 |
| Surprise Percentage | -80% | -25.8065% | 0% | 17.9487% | 60% | -115% | -61.6667% | 34.3284% | 88.0952% | -72.3077% | -49.5413% | 6.1404% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ANVS
2026-05-29 18:39:35
Maxim Group has reiterated its Buy rating for Annovis Bio (ANVS.US) and maintained its target price at $8. This indicates the firm's continued confidence in the biotechnology company's prospects.
2026-05-26 18:39:35
Annovis Bio, Inc. announced it has regained compliance with NYSE continued listing standards, just 12 months after being notified of non-compliance. The company's average global market capitalization and stockholders' equity fell below NYSE requirements, but swift action corrected the issue. Annovis Bio specializes in developing treatments for neurodegenerative diseases and will now focus on advancing its clinical programs.
2026-05-26 17:40:06
Annovis Bio Inc. (NYSE: ANVS) announced that it has regained compliance with the NYSE's continued listing standards, just 12 months after receiving a non-compliance notice. The company resolved the issue, which stemmed from its market capitalization and stockholders' equity falling below required thresholds. With compliance restored, Annovis Bio will focus on advancing its clinical programs for neurodegenerative diseases.
2026-05-26 17:40:06
Annovis Bio Inc. announced it has regained compliance with NYSE listing standards ahead of schedule, with its market capitalization now at $94.87 million, comfortably above the $50 million threshold. The company's stock, trading under ANVS, has seen a 15% gain recently but is down 55% over the past six months, with analysts viewing it as overvalued despite its strong cash position. Annovis Bio, a Phase 3 clinical-stage biotechnology company, is focused on advancing its clinical programs, including a Phase 3 Alzheimer’s disease study, and recently completed a $15 million public offering.
2026-05-26 12:08:51
Annovis Bio (NYSE: ANVS) announced it has regained compliance with NYSE continued listing standards after its average global market capitalization and stockholders' equity fell below $50 million in March 2025. The company implemented corrective actions and restored both metrics above the required thresholds within 12 months, well ahead of the 18-month cure period granted by the NYSE. With compliance achieved, Annovis will continue to focus on its pivotal Phase 3 Alzheimer’s study and upcoming regulatory submissions.
2026-05-23 04:10:19
Annovis Bio Inc. (NYSE: ANVS) has a consensus price target of $30.86 based on ratings from 8 analysts, with a high of $67 and a low of $9. The three most recent analyst ratings suggest an implied 541.25% upside for the company. Canaccord Genuity recently maintained a buy rating with a $17 price target, expecting a significant rise within 12 months.
